Doctors Note Logo

Published on: 9/28/2026

C. diff Poop: What It Looks and Smells Like, and How It Is Tested

C. diff diarrhea is typically watery or loose, often yellowish, greenish, or mucus-streaked, and it may occur three or more times a day for several days, sometimes with visible blood. The odor is frequently described as unusually strong and foul, and some people notice a distinctly sickly sweet or rotting smell, though smell alone cannot confirm the infection. Diagnosis relies on a stool sample tested by PCR/NAAT for toxin genes, EIA toxin A/B assays, or GDH antigen screening, and in some cases a colonoscopy to look for pseudomembranous colitis. Because recent antibiotic use, hospitalization, age, and other conditions strongly influence both risk and testing decisions, there are several important details to consider before assuming a cause, all of which are explained below.

If your stool has changed in appearance or odor and you are unsure whether it points to C. diff, another infection, or something else entirely, a few minutes of clarity can save you days of worry and help you decide whether same-day care is warranted; a free, instant, online symptom check lets you describe what you are seeing, understand the most likely explanations, and walk into your appointment knowing which questions and tests to ask about.

Last reviewed for medical accuracy: 09/28/2026

answer background

Explanation

C. diff Poop: What It Looks and Smells Like, and How It Is Tested

Understanding changes in your bowel movements can help you spot potential issues early. One infection that can cause dramatic shifts in stool appearance and odor is Clostridioides difficile, often called C. diff. In this guide, we’ll break down what c diff poop looks and smells like, how it’s diagnosed, and when to seek help—without exaggerating or sugar-coating the facts.


What Is C. diff?

Clostridioides difficile is a bacterium that can overgrow in your gut, especially after antibiotic use. While many people carry it harmlessly, an imbalance in gut bacteria may allow C. diff to produce toxins, triggering symptoms that range from mild diarrhea to life-threatening colitis.

Common risk factors include:

  • Recent antibiotic treatment
  • Hospital stays or nursing home residence
  • Weakened immune system
  • Age over 65

Recognizing C. diff Poop

C. diff alters the appearance, consistency, and smell of your stool. While not every change means C. diff, being aware of the typical signs can help you decide when to get tested.

Appearance

  • Color

    • Pale brown, grayish, or greenish hues
    • Sometimes streaks of blood or mucus
  • Consistency

    • Watery to semi-formed
    • Frequent loose, “explosive” stools
  • Quantity & Frequency

    • Sudden increase in the number of bowel movements (often 3–10+ per day)
    • Small, urgent “spurts” rather than solid stools

Odor

  • Strong, foul smell

    • More pungent than typical diarrhea
    • Sour or “rotting” sulfur notes
  • Lingering odor

    • Difficult to mask with air fresheners or cleaning products

Associated Symptoms

In addition to c diff poop, you may notice:

  • Abdominal cramping or pain
  • Fever (often low-grade, but can be higher)
  • Nausea or mild vomiting
  • Loss of appetite
  • General fatigue

If you experience severe abdominal pain, signs of dehydration (dizziness, dry mouth), or bloody diarrhea, consider these as red flags and seek medical attention promptly.


When to Consider Testing

You don’t need a test every time you have diarrhea. Testing for C. diff is generally advised if you:

  • Have had diarrhea for more than 48 hours without improvement
  • Recently took antibiotics or were hospitalized
  • Show signs of moderate to severe dehydration or fever
  • Pass blood or large amounts of mucus in your stool

If you’re unsure, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help guide you on whether testing or medical evaluation is recommended.


How C. diff Is Tested

Diagnosing C. diff relies on stool tests that identify the bacterium or its toxins. A healthcare provider will decide which test is right based on your symptoms and risk factors.

1. GDH Antigen Test

  • What it detects: A common enzyme (glutamate dehydrogenase) produced by C. diff
  • Pros: Quick, cost-effective
  • Cons: Doesn’t confirm toxin production—used as an initial screen

2. Toxin Assays

  • What they detect: Toxins A and B produced by C. diff
  • Pros: Directly measures the harmful toxins
  • Cons: Slightly slower than GDH test; risk of false negatives

3. Polymerase Chain Reaction (PCR)

  • What it detects: DNA segments specific to toxin-producing C. diff
  • Pros: Highly sensitive and specific; rapid results
  • Cons: More expensive; may detect harmless colonization

4. Two-Step Algorithms

Many labs use a combination:

  1. GDH screening to catch most cases
  2. Toxin assay or PCR to confirm active infection

5. Repeat Testing

  • Generally not recommended within 7 days of a positive result
  • Helps avoid false positives from lingering bacterial DNA

Preparing for Your Test

  • Stool sample collection

    • Follow your healthcare provider’s instructions carefully
    • Use the sterile container provided
    • Return the sample promptly (same day if possible)
  • Before testing

    • Continue or stop any medications only as directed by your provider
    • Stay hydrated
  • After testing

    • Your doctor will interpret results in the context of your symptoms
    • A negative test with ongoing symptoms may mean additional evaluation

Treatment Overview

If your test confirms C. diff infection, treatment focuses on stopping the overgrowth and restoring healthy gut bacteria.

First-Line Antibiotics

  • Vancomycin (oral)
  • Fidaxomicin

These target C. diff directly, sparing more of your normal gut flora than older treatments.

Additional Measures

  • Hydration: Oral rehydration solutions or IV fluids if needed
  • Diet: Bland foods (e.g., bananas, rice, toast) while recovering
  • Probiotics: May help—but discuss with your doctor first

Recurrence Management

Around 20–25% of people relapse. Options include:

  • Extended or pulsed antibiotic regimens
  • Fecal microbiota transplant (FMT) in resistant cases

Preventing C. diff

Good hygiene and cautious antibiotic use are key prevention strategies:

  • Wash hands thoroughly with soap and water (alcohol hand sanitizers are less effective against spores)
  • Clean high-touch surfaces with hospital-grade disinfectants containing bleach
  • Only take antibiotics when medically necessary
  • Wear gloves and gowns if caring for someone with C. diff

When to Seek Immediate Help

C. diff can range from mild to severe. Contact a healthcare provider or visit the emergency department if you experience:

  • Severe abdominal pain or distension
  • High fever (above 102°F/39°C)
  • Signs of dehydration: dizziness, rapid heartbeat, very dry mouth
  • Blood in your stool or black, tarry stools
  • Inability to keep down fluids

Remember to speak to a doctor about any serious or life-threatening symptoms. Early intervention can prevent complications.


Key Takeaways

  • C. diff infection often leads to pale, watery, foul-smelling diarrhea—sometimes with blood or mucus.
  • Testing involves stool assays (GDH, toxins, PCR), often in a two-step approach.
  • Treatment centers on targeted antibiotics, hydration, and possibly probiotics or fecal transplant for recurrence.
  • Good hand hygiene and prudent antibiotic use can reduce your risk.

If you’re experiencing persistent or severe diarrhea, abdominal pain, or other concerning symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And always reach out to a healthcare professional for personalized advice and to discuss testing or treatment options.


Disclaimer: This information is for educational purposes and does not replace medical advice. If you have life-threatening or worsening symptoms, speak to a doctor immediately.

(References)

  • * Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991 Jul;13(1):39-41. doi: 10.1097/00005176-199107000-00007. PMID: 1919950.

  • * Katz KC, Gardam MA, Burt J, Conly JM. A comparison of multifaceted versus Clostridium difficile-focused VRE surveillance strategies in a low-prevalence setting. Infect Control Hosp Epidemiol. 2001 Apr;22(4):219-21. doi: 10.1086/501896. PMID: 11379713.

  • * Tanner HE, Hardy KJ, Hawkey PM. Coexistence of multiple multilocus variable-number tandem-repeat analysis subtypes of Clostridium difficile PCR ribotype 027 strains within fecal specimens. J Clin Microbiol. 2010 Mar;48(3):985-7. doi: 10.1128/JCM.02012-09. Epub 2010 Jan 13. PMID: 20071546; PMCID: PMC2832431.

  • * Verhoeven PO, Carricajo A, Pillet S, Ros A, Fonsale N, Botelho-Nevers E, Lucht F, Berthelot P, Pozzetto B, Grattard F. Evaluation of the new CE-IVD marked BD MAX Cdiff Assay for the detection of toxigenic Clostridium difficile harboring the tcdB gene from clinical stool samples. J Microbiol Methods. 2013 Jul;94(1):58-60. doi: 10.1016/j.mimet.2013.04.009. Epub 2013 May 3. PMID: 23643507.

  • * Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am. 2015 Mar;29(1):109-22. doi: 10.1016/j.idc.2014.11.009. PMID: 25677705; PMCID: PMC4328137.

  • * Stollman N, Smith M, Giovanelli A, Mendolia G, Burns L, Didyk E, Burgess J, Noh A, Edelstein C, Alm E, Kassam Z. Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. Am J Gastroenterol. 2015 Apr;110(4):600-1. doi: 10.1038/ajg.2015.81. PMID: 25853204.

  • * Hibbard J, Jiang ZD, DuPont HL. Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection. Anaerobe. 2019 Apr;56:102-105. doi: 10.1016/j.anaerobe.2019.03.006. Epub 2019 Mar 6. PMID: 30851429.

  • * Youngster I. Another Step in the Journey-From Feces to Regulated Microbial Therapeutics. Clin Infect Dis. 2021 Oct 5;73(7):e1621-e1623. doi: 10.1093/cid/ciaa1435. PMID: 32961549.

  • * Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin-Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clin Infect Dis. 2021 Jun 1;72(11):e876-e880. doi: 10.1093/cid/ciaa1486. PMID: 33159210.

  • * Demirci B, Vergili GNC, Aydın F, Gülhan B, Yücel SP, Erat T, Yahşi A, Özen S, Bayhan Gİ, Özkaya-Parlakay A, Kanık-Yüksek S. Clinical impact of toxin detection in children with PCR-confirmed Clostridioides difficile infection. Eur J Pediatr. 2026 May 18;185(6). doi: 10.1007/s00431-026-07084-1. Epub 2026 May 18. PMID: 42144455.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.